Skip to content

Insider · CIK 0002016173

Sharma Amit

director

Files at CKPT (Checkpoint Therapeutics, Inc.). First filing -, latest -.

Sharma Amit files SEC Form 4 as director at CKPT (Checkpoint Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.

A track record needs three past buys with six months of prices behind them; Sharma Amit has 0, so none is measured yet.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, 2 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
May 28, 2025CKPT
Checkpoint Therapeutics, Inc.
AGrant or award
COMMON STOCK
+12,195$0.00$094,246May 30, 2025
May 30, 2025CKPT
Checkpoint Therapeutics, Inc.
UTender of shares
COMMON STOCK
-94,246--0May 30, 2025

Questions about Sharma Amit

Answered from the filings on this page, as of the latest one.

Is Sharma Amit buying or selling?

Sharma Amit has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.

How did Sharma Amit's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sharma Amit has 0.

Where does Sharma Amit file Form 4?

Sharma Amit has filed Form 4 at CKPT (Checkpoint Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.